Exelixis, Inc., an internationally focused oncology firm, revealed findings from a subgroup analysis of the phase 3 CABINET pivotal trial involving patients with extra-pancreatic neuroendocrine tumours (epNET) originating in the gastrointestinal...
The government is expected to grant an extension until December this year for the drug manufacturers to comply with the updated Schedule M. They stated that the drug regulations will be revised to allow for an extension of time. Once the last...
Innate Pharma SA reported that the initial patient has been dosed in its Phase 1 trial (NCT06781983), evaluating the safety and tolerability of IPH4502, a novel Antibody-Drug Conjugate (ADC), in individuals with advanced solid tumors expressing...
Apollo Hospitals Enterprise has entered into a Memorandum of Understanding (MoU) with Mayapada Healthcare Group in Indonesia. The collaboration, as stated by the healthcare leader, is poised to revolutionize the region's healthcare environment by...
Novo Nordisk, a prominent global healthcare firm, reported topline outcomes from a phase 1b/2a clinical trial involving amycretin, a unimolecular GLP-1 and amylin receptor agonist designed for weekly subcutaneous administration. The study...
Zerion Pharma A/S creates its own unique drug formulations and provides its Dispersome technology platform, announcing a collaboration with Aché Laboratórios Farmacêuticos S.A. (Aché), a leading pharmaceutical company in Brazil. The collaboration...
Eisai Co., Ltd. and Biogen Inc. announced that the U.S. Food and Drug Administration (FDA) has granted approval for the Supplemental Biologics License Application (sBLA) for lecanemab-irmb, administered intravenously (IV) once every four weeks as...
Rakuten Medical, Inc., a worldwide biotechnology firm focused on developing and commercializing precision, cell-targeting Alluminox platform-based photoimmunotherapy, declared the launch of its global multi-regional phase 3 clinical trial...
Pharmaceutical company Lupin announced that it has received authorization from the US health authority to commercialize generic HIV drug in the US market. The Mumbai-based drug manufacturer announced in a statement that it has obtained provisional...
Jaguar Health, Inc. (Jaguar) affiliated companies Napo Pharmaceuticals (Napo) and Napo Therapeutics announced that the first patient has received a dose in the independent investigator-led POC trial of crofelemer, Jaguar's innovative plant-derived...